Scientists track every puff: heated tobacco study reveals Real-World smoking habits
NCT ID NCT07677280
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study looks at how cigarette smokers use heated tobacco devices (glo and glo plus) at home for five days. About 200 participants in the UK will use the devices and report their puffing patterns through built-in sensors and daily surveys. The goal is to measure puff count, volume, duration, and how often people use the devices, helping researchers understand real-world usage behavior.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Heated tobacco products (glo and glo plus devices with tobacco or menthol sticks)
- What this could lead to
- If successful, this could help understand how people use heated tobacco products, potentially informing future product design or regulation.
- What could go wrong
- This is an observational study with a small sample over only five days, so results may not reflect long-term use or apply to all smokers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Ability to read, understand, and be willing to sign an ICF and complete questionnaires written in English. * Generally healthy male or female, between age 21-65 years (inclusive at the time of consent), verified with government-issued identification. * All female (assigned at birth) candidate participants and those who identify as "intersex" or "unknown" during screening who agree to take the pregnancy test on site and receive a negative result, and who affirm at the SEV that they are not pregnant or intending to become pregnant. * Self-report currently smoking at least five CPD on smoking days in the past 30 days. * Smoke CC on at least 27 days out of last 30 days. * Have smoked at least 100 factory-made filtered CC in their lifetime prior to SEV. * Indicate a willingness to use an HTP. * Agree to participate in the study and to abide by the study restrictions and requirements, including the use of the assigned Study IP, as described in the ICF. * Agree not to allow any other person to use any product provided to them for use during this study. Exclusion Criteria: * Female participants who self-report they are pregnant or breastfeeding or could become pregnant or start breastfeeding in the next 6 months from the study start date. * Women who self-report they are not intending to use adequate contraception methods to prevent pregnancy. a) Examples of acceptable contraception methods are, but not limited to: i. Surgical sterilization (hysterectomy, bilateral tubal ligation/occlusion, bilateral oophorectomy, bilateral salpingectomy); ii. Established use of oral, implantable, injectable, or transdermal methods of contraception associated with inhibition of ovulation; iii. Physical barrier method (e.g., condom, diaphragm/sponge/cervical cap) with spermicide; iv. Non-hormone releasing intrauterine devices (IUD) or hormone-releasing IUDs (e.g., Mirena or Kyleena); v. Vasectomized partner; vi. Abstinence from heterosexual intercourse (as a lifestyle choice, not just for the purpose of study participation); and vii. Post-menopausal who are not on hormone replacement therapy. * Males who self-report they are not willing to use a barrier method of contraception (e.g., a condom with spermicide) or to refrain from donating sperm from the time of signing the informed consent until the EOS, unless they have undergone a vasectomy or were abstinent from heterosexual intercourse, or their female partner was not able to bear children. * Individuals who self-report having pacemakers or other embedded electronic medical devices. * Individuals who self-report having an unstable heart condition, severe hypertension or diabetes. * Individuals who self-report they are sensitive to nicotine. * Individuals who respond with 'Poor' or 'Don't know' to general physical or mental health. * Individuals who have used a nicotine replacement therapy (NRT) product or a prescription drug to help stop smoking (e.g., varenicline, bupropion) in the past 30 days. * Individuals who are employed by a company that manufactures tobacco, HTPs, marketing or in ongoing litigation with a tobacco company. * Individuals who self-report that they are planning to quit all nicotine products in the next three months. * Individuals who are personally, have household members, or have close family or friends in ongoing or past litigation with a company that manufactures tobacco or HTPs. * People who have taken part in a tobacco/nicotine research study in the past 30 days.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cigarette smokers are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Channing Hall
Sheffield, United Kingdom
-
Cheshunt Community Sports Park
Cheshunt, United Kingdom